share_log

BRIEF-TG Therapeutics Announces Publication Of Final Results From The Phase 3 Genuine Trial Evaluating Ublituximab Plus Ibrutinib In Patients With Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia In The Lancet Haematology

BRIEF-TG Therapeutics Announces Publication Of Final Results From The Phase 3 Genuine Trial Evaluating Ublituximab Plus Ibrutinib In Patients With Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia In The Lancet Haematology

Brief-TG治療公司宣佈公佈評估Ublituximab加Ibrutinib治療柳葉刀血液學中復發/難治性高危慢性淋巴細胞白血病患者的第三階段真實試驗的最終結果
Reuters ·  2021/02/23 20:32

Feb 23 (Reuters) - TG Therapeutics Inc TGTX.O :

路透2月23日電-TG治療公司TGTX.O：

* TG THERAPEUTICS ANNOUNCES PUBLICATION OF FINAL RESULTS FROM THE PHASE 3 GENUINE TRIAL EVALUATING UBLITUXIMAB PLUS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA IN THE LANCET HAEMATOLOGY

*TG治療公司宣佈公佈評估UBLITUXIMAB加伊布魯替尼治療柳葉刀血液學中復發/難治性高危慢性淋巴細胞白血病患者的3期真實試驗的最終結果

Source text for Eikon: Further company coverage:

Eikon的源文本：進一步的公司報道：

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論